Baker Bros. Advisors LP Prelude Therapeutics Inc Transaction History
Baker Bros. Advisors LP
- $9.02 Billion
- Q4 2024
A detailed history of Baker Bros. Advisors LP transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Baker Bros. Advisors LP holds 10,123,824 shares of PRLD stock, worth $7.49 Million. This represents 0.14% of its overall portfolio holdings.
Number of Shares
10,123,824
Previous 10,123,824
-0.0%
Holding current value
$7.49 Million
Previous $21 Million
38.65%
% of portfolio
0.14%
Previous 0.22%
Shares
2 transactions
Others Institutions Holding PRLD
# of Institutions
59Shares Held
30.4MCall Options Held
6.4KPut Options Held
0-
Orbimed Advisors LLC San Diego, CA10.9MShares$8.07 Million0.38% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$790,9970.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.03MShares$761,6070.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.01MShares$747,6900.0% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ667KShares$493,2640.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $26.9M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...